Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T21:02:41.523Z Has data issue: false hasContentIssue false
  • English
  • Français

“Somatic” Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer

Published online by Cambridge University Press:  27 January 2021

Esther Knapp
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns: Currents in Contemporary Bioethics
Information
Journal of Law, Medicine & Ethics , Volume 48 , Issue 4: Climate Change and the Legal, Ethical, and Health Issues Facing Healthcare and Public Health Systems , Winter 2020 , pp. 778 - 783
Copyright
Copyright © American Society of Law, Medicine and Ethics 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

DeLeonardis, K. et al., “When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?” Journal of Oncology Practice 15, no. 9 (2019): 465–473; Mandelker, D. et al., “Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing,” Journal of the American Medical Association 318, no. 9 (2017): 825–835; Meric-Bernstam, F. et al., “Incidental Germline Variants in 1000 Advanced Cancers on a Prospective Somatic Genomic Profiling Protocol,” Annals of Oncology 27, no. 5 (2016): 795–800; Mody, R.J. et al., “Use of Integrative Clinical Sequencing in the Management of Pediatric Cancer Patients,” Journal of the American Medical Association 314, no. 9 (2015): 1–13; Schrader, K.A. et al., “Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA,” Journal of the American Medical Association Oncology 2, no. 1 (2016): 104–111; Seifert, B.A. et al., “Germline Analysis from Tumor-germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings,” Clinical Cancer Research 22, no. 16 (2016): 4087–4094.CrossRefGoogle Scholar
Clark, D.F., Maxwell, K.N. et al., “Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing,” Journal of Clinical Oncology Precision Oncology 3 (2019): 1–11.Google Scholar
Brodeur, G. M. et al., “Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr.,” Clinical Cancer Research 23, no. 11 (2017): e1–e5; Lawrence, M.S. et al., “Mutational Heterogeneity in Cancer and the Search for New Cancer-associated Genes,” Nature 499, no. 7457 (2013): 214–218; Sweet-Cordero, E.A. and Biegel, J.A., “The Genomic Landscape of Pediatric Cancers: Implications for Diagnosis and Treatment,” Science 363, no. 6432 (2019): 1170–1175; Vogelstein, B. et al., “Cancer Genome Landscapes,” Science 339, no. 6127 (2013): 1546–1558.CrossRefGoogle Scholar
Mandelker, supra note 1; Mody, supra note 1; Zhang, J. et al., “Germline Mutations in Predisposition Genes in Pediatric Cancer,” New England Journal of Medicine 373, no. 24 (2015): 2336–2346.CrossRefGoogle Scholar
Gray, S.W. et al., “Physicians’ Attitudes about Multiplex Tumor Genomic Testing,” Journal of Clinical Oncology 32, no. 13 (2014): 1317–1323; Johnson, L.M. et al., “Integrating Next Generation Sequencing into Pediatric Oncology Practice: An Assessment of Physician Confidence and Understanding of Clinical Genomics,” Cancer 123, no. 12 (2017): 2352–2359.Google Scholar
Kalia, S.S. et al., “Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics,” Genetics in Medicine 19, no. 2 (2017): 249–255.Google Scholar
DeLeonardis, supra note 1.Google Scholar
Meric-Bernstam, supra note 1.Google Scholar
DeLeonardis, supra note 1.Google Scholar
Robson, M. E. et al., “American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility,” Journal of Clinical Oncology 33, no. 31 (2015): 3660–3667.Google Scholar
Li, M. M. et al., “Points to Consider for Reporting of Germline Variation in Patients Undergoing Tumor Testing: A Statement of the American College of Medical Genetics and Genomics (ACMG),” Genetics in Medicine 22, no. 7 (2020): 1142–1148.CrossRefGoogle Scholar
Raymond, V.M. et al., “Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories,” Journal of the National Cancer Institute 108, no. 4 (2016): 1–5.CrossRefGoogle Scholar
Id.Google Scholar
Id.Google Scholar
American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors, “Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents,” American Journal of Human Genetics 57, no. 5 (1995): 1233–1241; Botkin, J.R. et al., “Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents,” American Journal of Human Genetics 97, no. 1 (2015): 6–21; Ross, L.F. et al., “Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children,” Genetics in Medicine 15, no. 3 (2013): 234–245; Ross, L.F. et al., “Erratum: Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children,” Genetics in Medicine 15, no. 4 (2013): 321.Google Scholar
Wilfond, B.S. et al., “Disclosing Secondary Findings from Pediatric Sequencing to Families: Considering the ‘Benefit to Families,’” Journal of Law, Medicine & Ethics 43, no. 3 (2015): 552–558.Google Scholar